Pfizer and Sciwind Biosciences
Type: License agreement
In-Licensee: Pfizer
Out-Licensor: Sciwind Biosciences
Focus: Ecnoglutide
Upfront Payment: Undisclosed
Milestone payments: $495 million
Financial impact: This partnership for ecnoglutide provides Sciwind with upfront and milestone payments that strengthen its finances and validate its metabolic pipeline, while granting Pfizer exclusive commercialisation rights in China to expand its presence in the high-demand GLP-1 market and drive long-term growth in diabetes and weight-management therapies.
Pfizer has signed a licensing deal with Sciwind Biosciences to commercialise ecnoglutide, a GLP-1 receptor agonist for type 2 diabetes, in mainland China, with total payments of up to $495 million tied to regulatory and sales milestones. Approved by China’s NMPA in January 2026, the injectable therapy has shown strong glucose-lowering and weight-loss results in clinical trials, while an additional indication for chronic weight management is under review. Sciwind will retain marketing authorisation and oversee R&D, manufacturing, and supply, as Pfizer strengthens its position in China’s growing metabolic disease market.
Ecnoglutide
Ecnoglutide is a long-acting, cAMP-biased GLP-1 analogue developed by Hangzhou Sciwind Biosciences in both once-weekly subcutaneous (XW003) and oral (XW004) formulations for obesity, type 2 diabetes, MASH, and obstructive sleep apnea. By selectively enhancing cAMP signaling while limiting β-arrestin recruitment, it aims to sustain receptor activity and improve metabolic outcomes. GLP-1–based therapies stimulate glucose-dependent insulin release, suppress glucagon secretion, reduce appetite, slow gastric emptying, and enhance glucose control.
The subcutaneous form is approved in China for the treatment of type 2 diabetes and is currently under regulatory review for the treatment of obesity, with global development ongoing. In Phase 2 studies, ecnoglutide demonstrated up to 13.2% weight loss, with 77–87% of patients achieving ≥5% weight reduction, and up to 71.9% reaching HbA1c ≤6.5% over 20 weeks. It has been generally well tolerated, with mainly mild-to-moderate gastrointestinal side effects such as nausea and diarrhea.
Eleven years' market revenue of Pfizer
Pfizer recorded steady revenue growth from 2015 to 2019, followed by a decline in 2020 mainly due to COVID-19–related disruptions to its non-COVID portfolio, reduced healthcare visits, supply chain challenges, generic competition, and the spin-off of its Upjohn business and merger with Viatris. Although its COVID-19 vaccine was launched in late 2020, meaningful revenue contribution was reflected in 2021.
After peaking in 2021–2022, revenue declined again as pandemic-driven sales of Comirnaty and Paxlovid dropped sharply due to lower vaccination rates, reduced government orders, and normalisation of demand, while growth in non-COVID products was insufficient to fully offset the decline.
Eleven years of market revenue of Pfizer (2015-2025)
Fig 9: Market revenue of Pfizer
Market Impact of This Partnership
This partnership between Pfizer and Sciwind Biosciences over ecnoglutide is seen as strategically significant for both firms and the broader diabetes/obesity market:
For Pfizer:
- Boosts its presence in China’s fast-growing metabolic disease market: The deal gives Pfizer exclusive commercialization rights in mainland China for ecnoglutide, strengthening its footprint in diabetes and obesity therapy where competition from rivals like Novo Nordisk and Eli Lilly is strong.
- Part of a broader strategy: It builds on Pfizer’s recent investments and collaborations in GLP-1 and weight-management drugs, helping diversify its portfolio beyond COVID-19 products and aiming to capture market share in a high-growth therapeutic segment.
- Competitive positioning: By securing rights to a locally developed GLP-1 therapy with strong clinical data, Pfizer can better compete with global leaders and tailor offerings to Chinese patients and healthcare systems.
“The Pfizer–Sciwind partnership strengthens Pfizer’s foothold in China’s booming GLP-1 market while accelerating ecnoglutide’s commercialization through a strategic, milestone-driven alliance.”
For Sciwind Biosciences:
- Accelerated commercialisation: Partnering with Pfizer gives Sciwind access to an established commercial infrastructure and salesforce in China, potentially speeding uptake of ecnoglutide.
- Financial upside: The milestone-based payments deal can provide significant funding to support continued R&D and broader development plans.
Broader market impact:
- Strengthens competition: The partnership adds another player to China’s crowded GLP-1 and obesity treatment space, which may drive competition on pricing, access, and innovation.
- Spotlights China as an innovation hub: Deals like this underscore the growing role of Chinese biotech in global pharmaceutical pipelines, with multinationals increasingly licensing or co-developing innovative assets with local firms.
Overall, the partnership is viewed as enhancing Pfizer’s strategic position in a key therapeutic area and giving Sciwind’s ecnoglutide wider commercial reach.